Can Etest Be Used To Determine
            <i>Vibrio cholerae</i>
            Susceptibility to Erythromycin?

Ng, Lai-King; Sawatzky, Pam; Galas, Marcelo; Rodrigues, Dália dos Prazeres; Heitmann, Ingrid; Fernandez, Sandra; Bolmström, Anne

doi:10.1128/aac.47.4.1479-1480.2003

Cited by 7 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard CLSI breakpoints for erythromycin do not exist. MIC interpretation for erythromycin was performed using a previously published method (8). MIC breakpoints conferring resistance are listed in Fig.…”

mentioning

confidence: 99%

Genetic Characterization of Multidrug-Resistant, Extended-Spectrum- β-Lactamase-Producing Vibrio cholerae O1 Outbreak Strains, Mpumalanga, South Africa, 2008

et al. 2011

View full text Add to dashboard Cite

Thirty-one antimicrobial-resistant, extended-spectrum-β-lactamase-producing strains of Vibrio cholerae O1 serotype Ogawa associated with an outbreak of cholera in South Africa (2008) were investigated. Ten selected cholera strains were PCR positive for the SXT element, harbored mutations in the quinolone resistance-determining regions of GyrA (Ser83-Ile) and ParC (Ser85-Leu), and produced TEM-63 β-lactamase.

show abstract

mentioning

confidence: 99%

Genetic Characterization of Multidrug-Resistant, Extended-Spectrum- β-Lactamase-Producing Vibrio cholerae O1 Outbreak Strains, Mpumalanga, South Africa, 2008

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Tube dilution or automated MIC testing is for the most part not available, and E-tests for determining MICs, although adaptable to developing country settings and used for determining V . cholerae susceptibility to erythromycin,[ 35 ] are considerably more expensive (disc diffusion technique cost is $0.73 compared to E-test cost $7.31). Using resistance to nalidixic acid on disc-diffusion testing as a screening test for identifying Salmonella and N .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1

et al. 2015

View full text Add to dashboard Cite

ObjectiveWe identified a poor clinical response to treatment of cholera with a single 1 g dose of ciprofloxacin, a standard treatment for cholera.MethodsTo determine reasons for the poor response and better therapeutic approaches we examined the minimal inhibitor concentration (MIC, n = 275) and disc-diffusion zone sizes (n = 205) for ciprofloxacin and nalidixic acid of V. cholerae O1 strains isolated in Bangladesh from 1994 to 2012, and reexamined data from 161patients infected with Vibrio cholerae O1 recruited in four clinical trials who received single- or multiple-dose ciprofloxacin for treatment of cholera and compared their clinical response to the V. cholerae O1 susceptibility.ResultsAlthough all 275 isolates of V. cholerae O1 remained susceptible to ciprofloxacin using standard MIC and disc-diffusion thresholds, the MIC90 to ciprofloxacin increased from 0.010 in 1994 to 0.475 μgm/ml in 2012. Isolates became frankly resistant to nalidixic with the MIC90 increasing from 21 μgm/ml in 1994 to >256 μgm/ml and 166 of 205 isolates from 1994 to 2005 being frankly resistant using disc-diffusion testing. Isolates resistant to nalidixic acid by disc-diffusion testing had a median ciprofloxacin MIC of 0.190 μgm/ml (10th-90th centiles 0.022 to 0.380); nalidixic acid-susceptible isolates had a median ciprofloxacin MIC of 0.002 (0.002 to 0.012).The rate of clinical success with single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains was 94% (61 of 65 patients) and bacteriologic success 97% (63/65) compared to 18% (12/67) and 8% (5/67) respectively with nalidixic acid-resistant strains (P<0.001 for both comparisons). Multiple-dose treatment with ciprofloxacin had 86% and 100% clinical and bacteriologic success rates respectively in patients infected with nalidixic acid-susceptible strains of V. cholerae O1 compared to clinical success 67% and bacteriologic success 60% with nalidixic acid-resistant strains.ConclusionsSingle-dose ciprofloxacin is not effective for treating cholera caused by V. cholerae O1 with diminished susceptibility to ciprofloxacin, and nalidixic acid disc-diffusion testing effectively screens for such isolates.

show abstract

“…Antimicrobial susceptibility testing was performed on Mueller-Hinton Agar (Diagnostic Media Products) using the Etest method (bioMérieux); the following antimicrobials were tested: ampicillin, ceftriaxone, cotrimoxazole, chloramphenicol, nalidixic acid, ciprofloxacin, tetracycline, erythromycin and nitrofurantoin as an alternative to furazolidone. Minimum inhibitory concentration (MIC) breakpoints for determination of antimicrobial resistance are shown in Table 1 ; these were interpreted in accordance with the Clinical and Laboratory Standards Institute (CLSI) [ 33 ] with the exception of erythromycin which was interpreted according to breakpoints described by Ng and coworkers [ 34 ].…”

Section: Methodsmentioning

confidence: 99%

Comparative Characterization of Vibrio cholerae O1 from Five Sub-Saharan African Countries Using Various Phenotypic and Genotypic Techniques

et al. 2015

View full text Add to dashboard Cite

We used standardized methodologies to characterize Vibrio cholerae O1 isolates from Guinea, Democratic Republic of the Congo (DRC), Togo, Côte d’Ivoire and Mozambique. We investigated 257 human isolates collected in 2010 to 2013. DRC isolates serotyped O1 Inaba, while isolates from other countries serotyped O1 Ogawa. All isolates were biotype El Tor and positive for cholera toxin. All isolates showed multidrug resistance but lacked ciprofloxacin resistance. Antimicrobial susceptibility profiles of isolates varied between countries. In particular, the susceptibility profile of isolates from Mozambique (East-Africa) included resistance to ceftriaxone and was distinctly different to the susceptibility profiles of isolates from countries located in West- and Central-Africa. Molecular subtyping of isolates using pulsed-field gel electrophoresis (PFGE) analysis showed a complex relationship among isolates. Some PFGE patterns were unique to particular countries and clustered by country; while other PFGE patterns were shared by isolates from multiple countries, indicating that the same genetic lineage is present in multiple countries. Our data add to a better understanding of cholera epidemiology in Africa.

show abstract

Can Etest Be Used To Determine Vibrio cholerae Susceptibility to Erythromycin?

Cited by 7 publications

References 2 publications

Genetic Characterization of Multidrug-Resistant, Extended-Spectrum- β-Lactamase-Producing Vibrio cholerae O1 Outbreak Strains, Mpumalanga, South Africa, 2008

Genetic Characterization of Multidrug-Resistant, Extended-Spectrum- β-Lactamase-Producing Vibrio cholerae O1 Outbreak Strains, Mpumalanga, South Africa, 2008

Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1

Comparative Characterization of Vibrio cholerae O1 from Five Sub-Saharan African Countries Using Various Phenotypic and Genotypic Techniques

Contact Info

Product

Resources

About